Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$2.73 – $4.58
9% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.4M | $3.4M | $6.1M | $33.9M | $154.5M | $134.1M | $171.3M | $222.3M |
| Cost of revenue | $916.0K | $866.0K | $997.0K | $15.4M | $38.5M | $63.1M | $83.6M | $83.6M |
| Gross profit | $2.4M | $2.5M | $5.1M | $18.5M | $116.0M | $71.0M | $87.8M | $138.7M |
| Gross margin | 72.7% | 74.3% | 83.7% | 54.5% | 75.1% | 52.9% | 51.2% | 62.4% |
| R&D | $154.6M | $192.9M | $227.2M | $230.8M | $346.2M | $411.3M | $375.7M | $304.7M |
| Operating income | −$246.5M | −$359.7M | −$422.8M | −$547.0M | −$588.6M | −$788.5M | −$637.9M | −$517.8M |
| EBITDA | −$245.5M | −$351.7M | −$414.8M | −$538.8M | −$554.3M | −$705.5M | −$642.1M | −$371.2M |
| Net income | −$248.0M | −$360.0M | −$420.9M | −$548.3M | −$611.1M | −$831.7M | −$806.7M | −$534.1M |
| Net margin | -7384.6% | -10701.8% | -6901.5% | -1618.4% | -395.5% | -620.3% | -470.9% | -240.3% |
| EPS (diluted) | -6.47 | -9.00 | -9.98 | -12.33 | -13.60 | -15.83 | -12.84 | -6.55 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $187M | $1.23 | $0.01–$3.03 | 1 |
| 2027 | $447M | $-5.38 | $-13.31–$-0.06 | 1 |
| 2028 | $917M | $-2.40 | $-5.92–$-0.03 | 1 |
| 2029 | $2.1B | $4.01 | $0.05–$9.91 | 1 |
Forward consensus · source: Financial Modeling Prep
HANSA MEDICAL AB ORD
No one on the platform currently holds HNSBF.
No tracked institution reports a position in HNSBF as of their last filing.
No one on the platform has traded HNSBF yet.
| $134M |
| — |
| OPORFhVIVO plc | $0.11 | +0.00% | $75M | — |
| PBBIFProbi AB (publ) | $24.00 | +0.00% | $287M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.0× sales vs its 1.5× historical median P/S.
Fair value ≈ $4.27 · price $2.90 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.